Core Viewpoint - Marker Therapeutics, Inc. has received a 9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of its lead product MT-601 in patients with metastatic pancreatic cancer [1][5]. Group 1: Grant and Study Details - The CPRIT grant will support the Phase 1 PANACEA study, which evaluates the safety and tolerability of MT-601, a multi-tumor associated antigen-specific T cell product, in patients with metastatic pancreatic cancer [2]. - The company has received over 30 million in non-dilutive funding from various governmental institutions, including a recent $2 million grant from the NIH Small Business Innovation Research (SBIR) program [5][6]. Group 2: Product and Clinical Background - MT-601 is currently being studied for CD19-CAR relapsed lymphoma and has shown preliminary safety and efficacy with sustained objective responses in three participants [3]. - Previous studies have indicated that MT-601 can target multiple tumor-specific antigens, which may allow its application in solid tumors beyond lymphoma [4][9]. - A prior study at Baylor College of Medicine demonstrated favorable safety and durable cancer control in patients with pancreatic cancer treated with multiTAA-specific T cells [4]. Group 3: Company Overview - Marker Therapeutics is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [11]. - The company aims to introduce novel T cell therapies to the market while preserving financial resources and ensuring operational excellence [11].
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer